Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroStatics, a clinical stage biotechnology company developing therapeutics for viral and other chronic diseases, has obtained an exclusive license to a library of 300 compounds developed by Maurizio Botta at University of Siena in collaboration with Silvia Schenone at University of Genova and Giovanni Maga at IGM-CNR, Pavia, and to the patents associated therewith.
Subscribe to our email newsletter
The library consists of specifically designed molecules targeting key enzymes and processes involved in both cancer and viral diseases. ViroStatics will identify and develop candidate compounds with activity against HIV, hepatitis C, and other viruses using the company’s proprietary screening methodologies. Specific terms of the license agreement were not announced.
Franco Lori, president and CEO of ViroStatics, said: “ViroStatics is extremely honored to partner with professors Botta, Schenone, and Maga to acquire this impressive library of compounds with potential applications in the treatment of cancer, HIV/AIDS and other chronic infections.
“Using our proprietary methodologies for screening these agents, ViroStatics plans to quickly begin to identify candidate compounds to move into preclinical development.”